Результати пошуку - Edward M. Wolin

Уточнити результати
  1. 1
    Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung

    Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung за авторством Edward M. Wolin

    Опубліковано 2016
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors

    Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors за авторством Edward M. Wolin, John Leyden, Grace Goldstein, Teodora Kolarova, Ron Hollander, Richard R.P. Warner

    Опубліковано 2017
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Pharmacokinetic study of aldoxorubicin in patients with solid tumors

    Pharmacokinetic study of aldoxorubicin in patients with solid tumors за авторством Monica Mita, Ronald B. Natale, Edward M. Wolin, Brenda Laabs, Hillary Dinh, Scott Wieland, Daniel Levitt, Alain C. Mita

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

    Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study за авторством Martyn Caplin, Marianne Pavel, Alexandria T. Phan, Jarosław B. Ćwikła, Eva Sedláčková, Xuan-Mai Truong Thanh, Edward M. Wolin, Philippe Ruszniewski

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors

    Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors за авторством Mohammadali Hamiditabar, Ali Muzammil, Joseph Roys, Edward M. Wolin, Thomas M. O’Dorisio, David Ranganathan, Izabela Tworowska, Jonathan Strosberg, Ebrahim S. Delpassand

    Опубліковано 2017
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Impact of <sup>68</sup>Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

    Impact of <sup>68</sup>Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective за авторством Ken Herrmann, Johannes Czernin, Edward M. Wolin, Pawan Gupta, Martin Barrio, Antonio Gutiérrez, Christiaan Schiepers, Sherly Mosessian, Michael E. Phelps, Martin Allen-Auerbach

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs

    Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs за авторством Simron Singh, Donald Granberg, Edward M. Wolin, Richard R.P. Warner, Maia Sissons, Teodora Kolarova, Grace Goldstein, Marianne Pavel, Kjell Öberg, John Leyden

    Опубліковано 2016
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors за авторством Catherine Lombard‐Bohas, James C. Yao, Timothy J. Hobday, Eric Van Cutsem, Edward M. Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H. Shah, Jaume Capdevila, Rodney F. Pommier

    Опубліковано 2014
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

    Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors за авторством Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Joëlle Blumberg, Philippe Ruszniewski

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

    Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study за авторством Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Edda Gomez-Panzani, Philippe Ruszniewski, _ _

    Опубліковано 2016
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study

    Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study за авторством Éric Baudin, J. Capdevila, Dieter Hörsch, Simron Singh, M. Caplin, Edward M. Wolin, Wieneke A. Buikhuisen, Markus Raderer, Éric Dansin, Christian Grohé, Diego Ferone, A Houchard, X.-M. Truong-Thanh, Diane Reidy‐Lagunes, NULL AUTHOR_ID

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial

    Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial за авторством Jonathan Strosberg, Edward M. Wolin, Beth Chasen, Matthew H. Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Pamela L. Kunz, Timothy J. Hobday, Andrew Hendifar, Kjell Öberg, Maribel Lopera Sierra, Thomas Thevenet, Inés Margalet, Philippe Ruszniewski, Eric P. Krenning

    Опубліковано 2018
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Consensus on biomarkers for neuroendocrine tumour disease

    Consensus on biomarkers for neuroendocrine tumour disease за авторством Kjell Öberg, Irvin M. Modlin, Wouter W. de Herder, Marianne Pavel, David S. Klimstra, Andrea Frilling, David C. Metz, Anthony P. Heaney, Dik J. Kwekkeboom, Jonathan Strosberg, T Meyer, Steven F. Moss, Kay Washington, Edward M. Wolin, Eric Liu, James R. Goldenring

    Опубліковано 2015
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  14. 14
    Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

    Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: S... за авторством James C. Yao, Katherine A. Guthrie, César A. Moran, Jonathan Strosberg, Matthew H. Kulke, Jennifer A. Chan, Noelle K. LoConte, Robert R. McWilliams, Edward M. Wolin, Bassam Mattar, Shannon McDonough, Helen Chen, Charles D. Blanke, Howard S. Höchster

    Опубліковано 2017
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    Everolimus for Advanced Pancreatic Neuroendocrine Tumors за авторством James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg

    Опубліковано 2011
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

    Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis за авторством Nicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, Margot Tesselaar, Edward M. Wolin, Eric Van Cutsem, Paola Tomassetti, Jonathan Strosberg, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Antonia Ridolfi, Fabian Herbst, Jiří Tomášek, Simron Singh, Marianne Pavel, Matthew H. Kulke, Juan W. Valle, James C. Yao

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

    Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues за авторством Edward M. Wolin, Barbara Jarząb, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David R. Fogelman, John Ramage, Donald Poon, Brian Gadbaw, Li Jiang, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell‐Price, Wasat Mansoor, Kjell Öberg

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States

    Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States за авторством Li Zhu, Laura H. Tang, Xinwei Qiao, Edward M. Wolin, Nicholas N. Nissen, Deepti Dhall, Jie Chen, Lin Shen, Yihebali Chi, Yaozong Yuan, Qiwen Ben, Bin Lv, Yaru Zhou, Chunmei Bai, Jie Chen, Yu‐Li Song, Tiantian Song, Chongmei Lu, Run Yu, Yuan‐Jia Chen

    Опубліковано 2016
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

    Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary за авторством Simron Singh, Carlo Carnaghi, Roberto Buzzoni, Rodney F. Pommier, Markus Raderer, Jiří Tomášek, Harald Lahner, Juan W. Valle, Maurizio Voi, Lida Bubuteishvili‐Pacaud, Jeremie Lincy, Edward M. Wolin, Natsuko Okita, Steven K. Libutti, Do‐Youn Oh, Matthew H. Kulke, Jonathan Strosberg, James C. Yao, Marianne Pavel, Nicola Fazio

    Опубліковано 2017
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study за авторством James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel

    Опубліковано 2015
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: